Inactive Instrument
Company Vical Incorporated Nasdaq
Stocks
US9256022032
Biotechnology & Medical Research
Business description: Vical Incorporated
Sales by Activity: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Geographical breakdown of sales: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Executive Committee: Vical Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 74 | - |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2016 |
Aaron Fox-Collis
DFI | Director of Finance/CFO | - | 01/06/2022 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Company details: Vical Incorporated
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.41% | +0.29% | +39.41% | +72.14% | 64.69B | |
| -0.15% | +7.50% | +11.42% | +71.27% | 54.78B | |
| +0.57% | +4.60% | +7.71% | +90.93% | 53.49B | |
| +0.37% | +4.67% | +26.68% | +49.64% | 45.98B | |
| -1.21% | +2.32% | +21.50% | +118.33% | 42.94B | |
| -0.37% | +5.07% | +243.23% | +789.58% | 40.08B | |
| +0.05% | +0.21% | +18.06% | +48.50% | 33.52B | |
| +1.19% | -4.98% | +26.31% | -0.76% | 23.97B | |
| -0.38% | +5.68% | +38.39% | +28.35% | 23.67B | |
| Average | +0.28% | +2.41% | +48.08% | +140.89% | 42.57B | |
| Weighted average by Cap. | +0.39% | +2.73% | +46.02% | +142.84% |
